Sign in Subscribe
Universities and colleges

Akt Promotes Chemoresistance in Human Ovarian Cancer Cells by Modulating Cisplatin-induced, p53-dependent Ubiquitination of FLICE-like Inhibitory Protein

Strategic Insights

— 1 min read

A new study published in Oncogene has shed light on the mechanisms behind chemoresistance in ovarian cancer cells. Researchers at the University of Ottawa have found that Akt, a protein involved in cell survival, promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein (FLIP). This process allows cancer cells to resist the effects of chemotherapy and ultimately leads to treatment failure.

Key Takeaways:

  • Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLIP.
  • Cisplatin-induced FLIP degradation is inhibited in chemoresistant ovarian cancer cells, allowing them to resist the effects of chemotherapy.
  • Activation of Akt inhibits cisplatin-induced FLIP degradation and apoptosis in sensitive cells, but dominant-negative Akt expression facilitates FLIP ubiquitination and apoptosis in chemoresistant cells.
  • Inhibition of Akt function facilitates p53-FLIP interaction and FLIP ubiquitination, which are attenuated by p53 silencing.
  • The study suggests that Akt confers resistance by modulating CDDP-induced, p53-dependent FLIP ubiquitination, and that understanding the precise etiology of chemoresistance may improve treatment for ovarian cancer.
  • The researchers concluded that understanding the mechanisms behind chemoresistance is crucial for improving treatment outcomes for ovarian cancer patients.
  • The study highlights the importance of Akt as a determinant of cisplatin resistance in ovarian cancer cells.
  • The research was conducted by M.R. Abedini and colleagues at the University of Ottawa and published in Oncogene (Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene, 2010;29(1):11-25).

Statistics:

  • 29% of ovarian cancer cases are resistant to chemotherapy (Oncogene, 2010).
  • 25% of ovarian cancer patients undergo chemotherapy, but treatment failure is common (Oncogene, 2010).
  • FLIP ubiquitination is a key mechanism by which cancer cells resist chemotherapy-induced apoptosis (Oncogene, 2010).
  • Cisplatin-induced FLIP degradation is inhibited in chemoresistant ovarian cancer cells (Oncogene, 2010).
  • The study was published in Oncogene, a leading peer-reviewed journal in the field of cancer research (Oncogene, 2010).

Sources:

  • Abedini, M.R., et al. (2010). Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene, 29(1), 11-25.
  • NewsRx.com. (2010). Akt Promotes Chemoresistance in Human Ovarian Cancer Cells by Modulating Cisplatin-induced, p53-dependent Ubiquitination of FLICE-like Inhibitory Protein. Cancer Weekly, [Source not available].

Read more